Woś Halina, Sankiewicz-Szkółka Magda, Więcek Sabina, Kordys-Darmolińska Bożena, Grzybowska-Chlebowczyk Urszula, Kniażewska Maria
Department of Paediatrics of the Medical University of Silesia in Katowice, Medyków Street 16, 40-752 Katowice, Poland, tel. (32) 207-17-00, e-mail:
Dev Period Med. 2015 Jan-Mar;19(1):25-31.
Neonatal cystic fibrosis screening contributes to an early diagnosis of cystic fibrosis and to implementing appropriate therapeutic management. Long-standing screening tests have made it possible to identify a group of newborns in whom the diagnosis was ambiguous and required further specialised tests.
The aim is to present cases of patients with a positive result of newborn screening for cystic fibrosis who were found to be carriers of the mutation in both alleles, however the lack of clinical symptoms and correct sweat testing values did not lead doctors to diagnosing cystic fibrosis and by the same token implementing the treatment.
The analysis encompassed a group of 22 infants and children 3 months to 3 years of age, in whom, in spite of a positive result of newborn screening for cystic fibrosis and the presence of 2 mutations in the CFTR gene, the diagnosis of cystic fibrosis was not made, and appropriate treatment was not administered because of diagnostic doubts (due to correct concentration of chlorides in sweat, correct IRT level and lack of clinical signs of cystic fibrosis). The control group consisted of 55 children treated in our centre, in whom neonatal screening for cystic fibrosis was positive and the diagnosis was confirmed by genetic testing, sweat chloride testing and IRT concentration.
There were no differences in birth body weight between the groups. The differences in chlorideion levels in sweat secretion tests and mean IRT values were statistically significant and were: 97.5 for the control group and 26.4 for the test group. At the present time there are no clinical symptoms to give a diagnosis of cystic fibrosis and start treatment in the test group.
Newborn screening contributes not only to an early diagnosis of cystic fibrosis but also to CFTR-related metabolic syndromes (CRMS), which is a phenomenon requiring further observation. This fact constitutes a definite psychological problem for the parents of these patients. .
新生儿囊性纤维化筛查有助于早期诊断囊性纤维化并实施适当的治疗管理。长期的筛查测试使得识别出一组诊断不明确且需要进一步专业检查的新生儿成为可能。
目的是呈现新生儿囊性纤维化筛查结果为阳性但被发现两个等位基因均为突变携带者的患者病例,然而缺乏临床症状且汗液测试值正常,这使得医生未诊断出囊性纤维化,同样也未实施治疗。
分析纳入了一组年龄在3个月至3岁的22名婴幼儿,尽管他们的新生儿囊性纤维化筛查结果为阳性且CFTR基因存在两个突变,但由于诊断存疑(因汗液中氯化物浓度正常、IRT水平正常且缺乏囊性纤维化的临床体征),未做出囊性纤维化的诊断,也未给予适当治疗。对照组由在我们中心接受治疗的55名儿童组成,他们的新生儿囊性纤维化筛查呈阳性,且通过基因检测、汗液氯化物检测和IRT浓度检测确诊。
两组之间出生体重无差异。汗液分泌测试中氯离子水平和平均IRT值的差异具有统计学意义,分别为:对照组97.5,测试组26.4。目前测试组没有临床症状可诊断为囊性纤维化并开始治疗。
新生儿筛查不仅有助于早期诊断囊性纤维化,还有助于诊断与CFTR相关的代谢综合征(CRMS),这是一种需要进一步观察的现象。这一事实给这些患者的父母带来了明确的心理问题。